TREM2 Alzheimer's Disease Risk Genotyping Kit

Mutations at the TREM2 gene locus are among the clinically most valuable rare variants in Alzheimer's disease genetic risk research. Since first reported in The New England Journal of Medicine in 2013, it has been validated by more than 60 independent studies worldwide; carriers have a 2- to 4-fold increased disease risk, and its risk effect strength ranks first among non-APOE gene variants. This locus is located in the ligand-binding domain of the TREM2 protein and promotes AD pathological progression through multiple mechanisms, including weakening microglial clearance of β-amyloid, impairing synaptic pruning function, and exacerbating neuroinflammatory responses; moreover, carriers show significantly altered soluble TREM2 levels in cerebrospinal fluid and plasma, which can serve as a dynamic monitoring marker of disease progression. With advances in the development of TREM2-targeted agonists and gene therapy strategies, TREM2 genotyping detection can be used not only for early risk stratification and intervention timing assessment in asymptomatic high-risk populations, but also to provide enrollment criteria for patients participating in targeted drug clinical trials, promoting a paradigm shift in Alzheimer's disease from "symptomatic treatment" to "risk prediction and precision intervention," with important clinical application prospects and public health value.